Cargando…
Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prosta...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352472/ https://www.ncbi.nlm.nih.gov/pubmed/32575490 http://dx.doi.org/10.3390/ijms21124373 |
_version_ | 1783557646052229120 |
---|---|
author | Waldbillig, Frank Nitschke, Katja Abdelhadi, Abdallah von Hardenberg, Jost Nuhn, Philipp Nientiedt, Malin Weis, Cleo-Aron Michel, Maurice Stephan Erben, Philipp Worst, Thomas Stefan |
author_facet | Waldbillig, Frank Nitschke, Katja Abdelhadi, Abdallah von Hardenberg, Jost Nuhn, Philipp Nientiedt, Malin Weis, Cleo-Aron Michel, Maurice Stephan Erben, Philipp Worst, Thomas Stefan |
author_sort | Waldbillig, Frank |
collection | PubMed |
description | Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prostate hyperplasia (BPH) controls (n = 8, n = 11) were profiled for SMPDL3B expression with qRT-PCR. Publicly available PCa cohorts (Memorial Sloane Kettering Cancer Centre (MSKCC; n = 131, n = 29 controls) and The Cancer Genome Atlas (TCGA; n = 497, n = 53 controls)) served for validation. SMPDL3B’s impact on proliferation and migration was analyzed in PC3 cells by siRNA knockdown. In both cohorts, a Gleason score and T stage independent significant overexpression of SMPDL3B was seen in PCa compared to BPH (p < 0.001 each). A lower expression of SMPDL3B was associated with a shorter overall survival (OS) (p = 0.005) in long term follow-up. A SMPDL3B overexpression in PCa tissue was confirmed in the validation cohorts (p < 0.001 each). In the TCGA patients with low SMPDL3B expression, biochemical recurrence-free survival (p = 0.011) and progression-free interval (p < 0.001) were shorter. Knockdown of SMPDL3B impaired PC3 cell migration but not proliferation (p = 0.0081). In summary, SMPLD3B is highly overexpressed in PCa tissue, is inversely associated with localized PCa prognosis, and impairs PCa cell migration. |
format | Online Article Text |
id | pubmed-7352472 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73524722020-07-15 Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer Waldbillig, Frank Nitschke, Katja Abdelhadi, Abdallah von Hardenberg, Jost Nuhn, Philipp Nientiedt, Malin Weis, Cleo-Aron Michel, Maurice Stephan Erben, Philipp Worst, Thomas Stefan Int J Mol Sci Article Current outcome prediction markers for localized prostate cancer (PCa) are insufficient. The impact of the lipid-modifying Sphingomyelin Phosphodiesterase Acid Like 3B (SMPDL3B) in PCa is unknown. Two cohorts of patients with PCa who underwent radical prostatectomy (n = 40, n = 56) and benign prostate hyperplasia (BPH) controls (n = 8, n = 11) were profiled for SMPDL3B expression with qRT-PCR. Publicly available PCa cohorts (Memorial Sloane Kettering Cancer Centre (MSKCC; n = 131, n = 29 controls) and The Cancer Genome Atlas (TCGA; n = 497, n = 53 controls)) served for validation. SMPDL3B’s impact on proliferation and migration was analyzed in PC3 cells by siRNA knockdown. In both cohorts, a Gleason score and T stage independent significant overexpression of SMPDL3B was seen in PCa compared to BPH (p < 0.001 each). A lower expression of SMPDL3B was associated with a shorter overall survival (OS) (p = 0.005) in long term follow-up. A SMPDL3B overexpression in PCa tissue was confirmed in the validation cohorts (p < 0.001 each). In the TCGA patients with low SMPDL3B expression, biochemical recurrence-free survival (p = 0.011) and progression-free interval (p < 0.001) were shorter. Knockdown of SMPDL3B impaired PC3 cell migration but not proliferation (p = 0.0081). In summary, SMPLD3B is highly overexpressed in PCa tissue, is inversely associated with localized PCa prognosis, and impairs PCa cell migration. MDPI 2020-06-19 /pmc/articles/PMC7352472/ /pubmed/32575490 http://dx.doi.org/10.3390/ijms21124373 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Waldbillig, Frank Nitschke, Katja Abdelhadi, Abdallah von Hardenberg, Jost Nuhn, Philipp Nientiedt, Malin Weis, Cleo-Aron Michel, Maurice Stephan Erben, Philipp Worst, Thomas Stefan Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer |
title | Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer |
title_full | Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer |
title_fullStr | Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer |
title_full_unstemmed | Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer |
title_short | Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer |
title_sort | phosphodiesterase smpdl3b gene expression as independent outcome prediction marker in localized prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352472/ https://www.ncbi.nlm.nih.gov/pubmed/32575490 http://dx.doi.org/10.3390/ijms21124373 |
work_keys_str_mv | AT waldbilligfrank phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT nitschkekatja phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT abdelhadiabdallah phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT vonhardenbergjost phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT nuhnphilipp phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT nientiedtmalin phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT weiscleoaron phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT michelmauricestephan phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT erbenphilipp phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer AT worstthomasstefan phosphodiesterasesmpdl3bgeneexpressionasindependentoutcomepredictionmarkerinlocalizedprostatecancer |